Statement of Principles concerning Creutzfeldt-Jakob disease No. 76 of 2014

Administered by Department of Veterans' Affairs

Legislation au F2014L01138 Not in force Legislative Instrument

Legislation content

REPATRIATION MEDICAL AUTHORITY

 

INSTRUMENT NO. 76 of 2014

 

VETERANS’ ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

EXPLANATORY NOTES FOR TABLING

 

 

  1. The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA), revokes Instrument No. 34 of 2004, determined under subsection 196B(2) of the VEA concerning Creutzfeldt-Jakob disease.
  2. The Authority is of the view that there is sound medical-scientific evidence that indicates that Creutzfeldt-Jakob disease and death from Creutzfeldt-Jakob disease can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(2) of the VEA a Statement of Principles, Instrument No. 76 of 2014 concerning Creutzfeldt-Jakob disease.  This Instrument will in effect replace the revoked Statement of Principles.
  3. The provisions of the Military Rehabilitation and Compensation Act 2004 (the MRCA) relating to claims for compensation commenced on 1 July 2004.  Claims under section 319 of the MRCA for acceptance of liability for a service injury sustained, a service disease contracted or service death on or after 1 July 2004 are determined by the Military Rehabilitation and Compensation Commission by reference to Statements of Principles issued by the Authority pursuant to the VEA.
  4. The Statement of Principles sets out the factors that must as a minimum exist, and which of those factors must be related to the following kinds of service rendered by a person:

 operational service under the VEA;

 peacekeeping service under the VEA;

 hazardous service under the VEA;

 British nuclear test defence service under the VEA;

 warlike service under the MRCA;

 non-warlike service under the MRCA,

before it can be said that a reasonable hypothesis has been raised connecting Creutzfeldt-Jakob disease or death from Creutzfeldt-Jakob disease, with the circumstances of that service.

5.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 18 May 2011 concerning Creutzfeldt-Jakob disease in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

6.             The contents of this Instrument are in similar terms as the revoked Instrument.  Comparing this Instrument and the revoked Instrument, the differences include:

  • adopting the latest revised Instrument format, which commenced in 2005;
  • revising the definition of 'Creutzfeldt-Jakob disease' in clause 3;
  • new factor 6(a) concerning 'a specified human tissue or product';
  • revising factor 6(b) concerning 'neurosurgery';
  • revising factor 6(c)(i) concerning 'blood or blood products', for variant Creutzfeldt-Jakob disease only;
  • revising factor 6(c)(ii) concerning 'beef or a beef product', for variant Creutzfeldt-Jakob disease only;
  • deleting factors concerning 'human pituitary growth hormone', 'human pituitary gonadotrophins' and 'dura mater graft', as these factors are now covered by factor 6(a) concerning 'a specified human tissue or product';
  • new definitions of 'a beef product', 'a specified human tissue or product', 'bovine spongiform encephalopathy' and 'variant Creutzfeldt-Jakob disease' in clause 8;
  • revising the definitions of 'blood products', 'ICD-10-AM code' and 'relevant service' in clause 8;
  • deleting the definitions of 'a dura mater graft' and 'bovine spongiform encephalopathy infection'; and
  • specifying a date of effect for the Instrument in clause 10.

7.             Further changes to the format of the Instrument reflect the commencement of the MRCA and clarify that pursuant to subsection 196B(3A) of the VEA, the Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

8.             Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to Creutzfeldt-Jakob disease in the Government Notices Gazette of 18 May 2011, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority during the investigation.

9.             This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011. A Statement of Compatibility with Human Rights follows.

10.         The determining of this Instrument finalises the investigation in relation to Creutzfeldt-Jakob disease as advertised in the Government Notices Gazette of 18 May 2011.


11.         A list of references relating to the above condition is available to any person or organisation referred to in subsection 196E(1)(a) to (c) of the VEA.  Any such request must be made in writing to the Repatriation Medical Authority at the following address:

The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001

Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 76 of 2014

Kind of Injury, Disease or Death: Creutzfeldt-Jakob disease

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have Creutzfeldt-Jakob disease;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must as a minimum exist, before it can be said that a reasonable hypothesis has been raised, connecting Creutzfeldt-Jakob disease with the circumstances of eligible service rendered by a person, as set out in clause 4 of the Explanatory Notes;
  • replaces Instrument No. 34 of 2004; and
  • reflects developments in the available sound medical-scientific evidence concerning Creutzfeldt-Jakob disease which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICSECR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICSECR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members; and
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Repatriation Medical Authority Instrument No. 76 of 2014, enacted under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, was introduced to address the need for updated medical-scientific evidence concerning Creutzfeldt-Jakob disease in relation to certain kinds of military service. This instrument was determined by the Repatriation Medical Authority in response to a 2011 investigation into the disease, replacing the previous Statement of Principles No. 34 of 2004. The Authority found that there is sufficient evidence linking Creutzfeldt-Jakob disease to specific types of service and has set out new factors that must exist to establish a reasonable hypothesis connecting the disease with the service. The policy objective of this instrument is to ensure that claimants and the Repatriation Commission can effectively assess and determine claims for compensation and benefits, while also facilitating the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal. Furthermore, it aims to promote and protect human rights, including the right to social security and the right to health, for veterans, current and former Defence Force members, and their dependents.

Scope and Application

The Repatriation Medical Authority, as stipulated under the Veterans' Entitlements Act 1986, has revoked Instrument No. 34 of 2004 and issued Instrument No. 76 of 2014 concerning Creutzfeldt-Jakob disease. This instrument applies to persons who have contracted or died from Creutzfeldt-Jakob disease and are seeking benefits under the Veterans' Entitlements Act 1986 or the Military Rehabilitation and Compensation Act 2004, including veterans and current or former Defence Force members. The instrument specifies the minimum circumstances that must exist, linking the disease to certain types of service, such as operational, peacekeeping, hazardous, British nuclear test defence service, warlike, or non-warlike service. The instrument’s geographic reach is nationwide, applying to claims made within Australia under the specified acts. The instrument also clarifies that it is compatible with human rights, promoting rights such as social security, adequate living standards, health, and the rights of persons with disabilities. It does not derogate from any human rights and facilitates the assessment and determination of claims for treatment and rehabilitation benefits. Any changes to the instrument's application can be made through subordinate instruments, aligning with the provisions of the VEA and MRCA.

Key Provisions

The Repatriation Medical Authority Instrument No. 76 of 2014, under subsection 196B(8) of the Veterans' Entitlements Act 1986 (VEA), revokes Instrument No. 34 of 2004 concerning Creutzfeldt-Jakob disease and replaces it with a new Statement of Principles (section 1). This Instrument outlines the circumstances in which medical treatment and compensation can be extended to eligible individuals who have Creutzfeldt-Jakob disease (section 2). It specifies the minimum factors that must exist to raise a reasonable hypothesis connecting Creutzfeldt-Jakob disease with service rendered by a person, including operational, peacekeeping, hazardous, British nuclear test defence service, warlike, and non-warlike service (section 4). The Instrument also clarifies the definition of Creutzfeldt-Jakob disease and updates factors related to exposure to specified human tissues, neurosurgery, and blood or beef products (section 6). The Instrument imposes obligations on claimants and the Repatriation Commission to adhere to the specified factors for determining eligibility for benefits related to Creutzfeldt-Jakob disease (section 2). It requires claimants to provide evidence of their service and any relevant exposure to the factors outlined in the Statement of Principles. The Repatriation Commission must assess claims based on these factors and the sound medical-scientific evidence presented. Additionally, the Instrument mandates that the Veterans' Review Board and the Administrative Appeals Tribunal review decisions made under the VEA and the Military Rehabilitation and Compensation Act 2004 (MRCA) concerning such claims (section 2). There are no specific offences, penalties, or civil/criminal consequences outlined in the Instrument itself for breach of its provisions. However, any breach of the conditions specified in the Statement of Principles could result in the denial of benefits or compensation for claimants under the VEA or the MRCA. The focus of the Instrument is on facilitating the assessment and determination of claims for those affected by Creutzfeldt-Jakob disease, ensuring that claimants meet the specified criteria for eligibility (section 2). The compatibility of the Instrument with human rights is also emphasised, indicating that it does not derogate from any human rights and promotes the rights of veterans, Defence Force members, and their dependents (section 4).

Legal classification tags

Area of Law
Veterans' Law
Instrument
Statutory Instrument
Concepts
Definitions & Interpretation
Regulatory Standards
Reporting & Disclosure Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.